Raras
Buscar doenças, sintomas, genes...
Deficiência de alfa-1 antitripsina
ORPHA:60CID-10 · E88.0CID-11 · 5C5AOMIM 613490DOENÇA RARA

A deficiência de alfa-1-antitripsina é uma doença genética que se manifesta na idade adulta. Ela é caracterizada por problemas crônicos no fígado (como cirrose), problemas respiratórios (como enfisema) e, mais raramente, uma inflamação na gordura debaixo da pele (paniculite).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A deficiência de alfa-1-antitripsina é uma doença genética que se manifesta na idade adulta. Ela é caracterizada por problemas crônicos no fígado (como cirrose), problemas respiratórios (como enfisema) e, mais raramente, uma inflamação na gordura debaixo da pele (paniculite).

Pesquisas ativas
26 ensaios
159 total registrados no ClinicalTrials.gov
Publicações científicas
3.221 artigos
Último publicado: 2026 Apr 8
Medicamentos
1 registrados
DIPHENHYDRAMINE

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
DIPHENHYDRAMINE

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
47.5
Ireland
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: E88.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
8 sintomas
🫁
Pulmão
7 sintomas
🩸
Sangue
1 sintomas
📏
Crescimento
1 sintomas

+ 15 sintomas em outras categorias

Características mais comuns

100%prev.
Cirrose
Obrigatório (100%)
100%prev.
Concentração circulante reduzida de alfa-1-antitripsina
Obrigatório (100%)
100%prev.
Bronquiectasia
Obrigatório (100%)
100%prev.
Esplenomegalia
Obrigatório (100%)
100%prev.
Hemoptise
Obrigatório (100%)
100%prev.
Variz gástrica
Obrigatório (100%)
32sintomas
Muito frequente (10)
Frequente (9)
Ocasional (9)
Muito raro (2)
Sem dados (2)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 32 características clínicas mais associadas, ordenadas por frequência.

CirroseCirrhosis
Obrigatório (100%)100%
Concentração circulante reduzida de alfa-1-antitripsinaReduced circulating alpha-1-antitrypsin concentration
Obrigatório (100%)100%
BronquiectasiaBronchiectasis
Obrigatório (100%)100%
EsplenomegaliaSplenomegaly
Obrigatório (100%)100%
HemoptiseHemoptysis
Obrigatório (100%)100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico3.221PubMed
Últimos 10 anos200publicações
Pico2025150 papers
Linha do tempo
2026Hoje · 2026🧪 1988Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

SERPINA1Alpha-1-antitrypsinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin Reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respira

LOCALIZAÇÃO

SecretedEndoplasmic reticulumSecreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Alpha-1-antitrypsin deficiency

An autosomal recessive disorder characterized by serum levels of alpha-1-antitrypsin below the normal range, and an increased risk for developing pulmonary emphysema and, to a lesser extent, chronic liver disease. Environmental factors, particularly cigarette smoking, greatly increase the risk of emphysema at an earlier age.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
5944.3 TPM
Sangue
820.2 TPM
Pulmão
194.9 TPM
Rim - Medula
140.0 TPM
Intestino delgado
134.7 TPM
OUTRAS DOENÇAS (3)
alpha 1-antitrypsin deficiencycystic fibrosishemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation
HGNC:8941UniProt:P01009

Medicamentos e terapias

DIPHENHYDRAMINEPhase 1

Mecanismo: Histamine H1 receptor antagonist

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

134 variantes patogênicas registradas no ClinVar.

🧬 SERPINA1: NM_000295.5(SERPINA1):c.-5+1G>C ()
🧬 SERPINA1: NM_000295.5(SERPINA1):c.1174A>G (p.Lys392Glu) ()
🧬 SERPINA1: NM_000295.5(SERPINA1):c.1065+1G>A ()
🧬 SERPINA1: NM_000295.5(SERPINA1):c.979dup (p.Leu327fs) ()
🧬 SERPINA1: NM_000295.5(SERPINA1):c.613_614dup (p.Ala207fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 420 variantes classificadas pelo ClinVar.

84
168
168
Patogênica (20.0%)
VUS (40.0%)
Benigna (40.0%)
VARIANTES MAIS SIGNIFICATIVAS
SERPINA1: NM_000295.5(SERPINA1):c.-5+1G>C [Pathogenic]
SERPINA1: NM_000295.5(SERPINA1):c.628A>T (p.Asn210Tyr) [Likely pathogenic]
SERPINA1: NM_000295.5(SERPINA1):c.917+1G>A [Pathogenic]
SERPINA1: NM_000295.5(SERPINA1):c.1135del (p.Ala379fs) [Pathogenic]
SERPINA1: NM_000295.5(SERPINA1):c.32T>C (p.Leu11Pro) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 35
2Fase 23
1Fase 15
·Pré-clínico7
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Deficiência de alfa-1 antitripsina

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

17 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

159 ensaios clínicos encontrados, 26 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1.270 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.270

#1

Original research: Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency.

Hepatology (Baltimore, Md.)2026 Mar 11

Severe (Pi*ZZ) and heterozygous (Pi*MZ) alpha-1 antitrypsin deficiency (AATD) confer increased liver- and lung-related mortality, but the phenotype is highly variable. We aimed to evaluate the impact of obesity and diabetes mellitus on individuals with/without AATD. Cohort 1 prospectively recruited 1678 Pi*ZZ adults from an international initiative with a systematic liver assessment. 983 participants had a longitudinal follow-up. The data were compared to 16,768 Pi*MZ and 415,208 non-AATD individuals from the United Kingdom Biobank (cohort 2). Findings were ascertained by multivariable adjustment and propensity score matching. At baseline, diabetes was present in 52 (3%), overweight (BMI 25.0-29.9 kg/m2) in 540 (52%) and obesity (BMI≥30 kg/m2) in 266 (32%) Pi*ZZ adults. Pi*ZZ individuals with diabetes showed higher transaminases and surrogates of advanced liver fibrosis (APRI≥1.0, LSM≥15 kPa) were four to six times more common (adjusted Odds Ratio (aOR) 5.7/4.3, p<0.01). Elevated transaminases were rare among lean Pi*ZZ subjects, but more common in overweight (aOR 1.5/2.0) and obese Pi*ZZ participants (aOR 2.1/2.9). APRI≥1.0 was more than four times elevated in obese vs. lean Pi*ZZ individuals (aOR 4.1, p<0.001). During a median follow-up of 4.2 years, 54 Pi*ZZ participants experienced a hepatic and 64 a pulmonary endpoint. While Pi*ZZ participants with diabetes/obesity had an increased risk of hepatic endpoints (aHR 6.03/3.38, p<0.001) compared with non-diabetic/lean Pi*ZZ subjects, overweight was associated with a decreased risk of pulmonary endpoints (aHR 0.45, p=0.004). Our data demonstrate the interaction between genetic and metabolic risk factors in AATD and provide evidence for patient management.

#2

Prevalence of liver disease and liver transplantation in pediatric ZZ alpha-1 antitrypsin deficiency: A systematic review and meta-analysis.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2026 Mar 05

Pediatric Pi*ZZ alpha-1 antitrypsin deficiency (A1ATD) can cause hepatocyte A1AT polymer retention and progressive liver injury, but estimates of childhood liver morbidity vary across studies and remain poorly defined. To quantify liver-specific outcomes in pediatric Pi*ZZ A1ATD. We systematically reviewed studies reporting liver-specific outcomes in children with confirmed Pi*ZZ/ZZ A1ATD (PROSPERO CRD42022335666). We extracted prevalence of fibrosis and cirrhosis, elevated liver enzymes, and liver transplantation. Random-effects meta-analysis pooled logit-transformed proportions (with sensitivity analyses assessing robustness to model assumptions). Thirteen studies including 398 children met inclusion criteria. Pooled prevalence was 41.3% (95% CI 29.6-54.0) for fibrosis and 17.3% (7.2-35.9) for cirrhosis, with substantial heterogeneity for cirrhosis (I2 78.6%). Liver transplantation prevalence was 10.7% (6.3-13.0). Elevated liver enzymes occurred in 43.0% (19.2-70.5) with high heterogeneity (I2 89.4%). Across cohorts, the proportion with elevated liver enzymes declined with increasing mean age, despite ongoing liver disease in reported histology-based outcomes. Clinically important liver disease occurs in a substantial subset of children with Pi*ZZ A1ATD. Declining rates of elevated liver enzymes with age should not be interpreted as disease resolution. Standardized registries are needed for longitudinal surveillance, to identify disease modifiers, and to guide early intervention in this high-risk population.

#3

Alpha-1 Antitrypsin Deficiency in Patients With Cirrhosis in a US National Cohort.

Clinical and translational gastroenterology2026 Feb 16

Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that increases susceptibility to chronic lung and liver diseases. There are limited data on testing rates in patients with cirrhosis. Guidelines recommend AATD testing in cryptogenic liver disease but not in patients with an established etiology. We aimed to quantify AATD testing patterns in a national cohort of patients with cirrhosis to inform guidelines. In this retrospective cohort study of veterans with a new diagnosis of cirrhosis between January 1, 2008 and January 31, 2020, with follow-up until February 23, 2023, we identified predictors of testing, and of severe AATD (alpha-1 antitrypsin [AAT] < 57 mg/dL or PiSZ/PiZZ phenotype/genotype). Of the 126,210 patients with cirrhosis, 42,403 (33.6%) were tested, including 38,189 (30.3%) for AAT levels only, 1,103 (0.8%) for genotype/phenotype only, and 3,011 (2.4%) for both. Factors associated with higher AATD testing included specialist evaluation and White race, whereas patients with chronic obstructive pulmonary disease, hepatitis B/C, hepatocellular carcinoma, and hepatic decompensation were less likely to be tested. Only half of the patients with AAT levels of <57 mg/dL underwent genotype/phenotype testing. Most patients (94.7%) with severe AATD-associated liver disease also had an alternate etiology of liver disease, including metabolic dysfunction associated with steatotic liver disease (53.6%) or viral hepatitis (16.1%), and would be missed if testing only patients with cryptogenic liver disease. AATD testing rates in veterans with cirrhosis are low, and patients at high-risk are less likely to be tested. Guidelines are needed to emphasize universal AATD testing in patients with cirrhosis regardless of the presence of other risk factors.

#4

Isolated GGT elevation in prolonged neonatal jaundice: detection of heterozygous alpha-1 antitrypsin deficiency.

BMJ case reports2026 Feb 02

Prolonged neonatal jaundice is usually benign but can occasionally indicate serious hepatobiliary disease. Current UK guidelines emphasise bilirubin-based screening, which may overlook atypical biochemical profiles. A term neonate presented with persistent jaundice but was otherwise well, with normal stools and urine. Bilirubin levels were normal, yet gamma-glutamyl transferase (GGT) was markedly elevated at 1101 U/L. Further testing revealed reduced alpha-1 antitrypsin (A1AT) levels and PiMZ heterozygosity. Imaging showed no structural abnormality. Over follow-up, transaminases-alanine aminotransferase and aspartate aminotransferase-rose, suggesting evolving hepatic involvement. Isolated GGT elevation, though uncommon, may represent the earliest clue to hepatobiliary disease. Heterozygous A1AT deficiency is not always benign and warrants ongoing biochemical surveillance. Clinicians should interpret guideline frameworks carefully to ensure atypical but clinically significant disease presentations are not overlooked.

#5

Advances in Precision Editing Therapies for Alpha-1 Antitrypsin Deficiency.

Human gene therapy2026 Jan 26

Genome and RNA editing modalities have revolutionized precision gene therapy, offering a safer alternative to traditional gene replacement approaches. Alpha-1 antitrypsin deficiency (AATD) is a compelling model for precision medicine because the disease mechanism is well defined-mutations in a single gene are responsible for both liver and lung pathology. In this review, we summarize the current preclinical and clinical efforts for AATD, with an emphasis on genome and RNA editing strategies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.054 artigos no totalmostrando 196

2026

Regenerative Nodule as a Diagnostic Dilemma in the Neonate With Acute Liver Failure and a Focal Liver Lesion.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
2026

Development and Validation of an Electronic Health Record Algorithm to Predict the Presence of Chronic Obstructive Pulmonary Disease.

International journal of chronic obstructive pulmonary disease
2026

Original research: Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency.

Hepatology (Baltimore, Md.)
2025

Searching for alpha-1 antitrypsin deficiency in patients with bronchiectasis: reducing idiopathic cases.

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
2026

Optimising pulmonary rehabilitation for α1-antitrypsin deficiency: a qualitative study of patient and clinician perspectives.

ERJ open research
2026

A guide to selecting high-performing antibodies for Alpha-1-antitrypsin (UniProt ID: P01009) for use in western blot, immunoprecipitation and flow cytometry.

F1000Research
2026

Demographic and physiologic differences between fibrotic and non-fibrotic CT subtypes of sarcoidosis.

Chest
2026

Prevalence of liver disease and liver transplantation in pediatric ZZ alpha-1 antitrypsin deficiency: A systematic review and meta-analysis.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2026

Novel mutation (Mangera-E288V) in alpha-1 antitrypsin deficiency.

Multidisciplinary respiratory medicine
2026

The absence of the alpha-1 band in serum protein electrophoresis as a clue to diagnosis of alpha-1 antitrypsin deficiency panniculitis.

JAAD case reports
2026

Alpha-1 antitrypsin deficiency: A persistently underrecognized condition.

Cleveland Clinic journal of medicine
2026

A state of the union on alpha-1 antitrypsin deficiency at the Veterans Health Administration.

Annals of the American Thoracic Society
2026

Clinical implications of a novel SERPINA1 variant c.236 T > A: Challenges in characterizing new rare alpha-1 antitrypsin mutations.

Molecular genetics and metabolism reports
2026

Radiomic profiling of chest CT in a cohort of sarcoidosis cases.

Scientific reports
2026

Alpha-1 Antitrypsin Deficiency in Patients With Cirrhosis in a US National Cohort.

Clinical and translational gastroenterology
2026

Alpha-1 Antitrypsin Deficiency: Current Landscape of Detection, Management, and Treatment.

Advances in therapy
2026

Characteristics of bronchiectasis in patients with different genotypes of severe α1-antitrypsin deficiency from the EARCO registry.

ERJ open research
2026

Bronchiectasis in severe α1-antitrypsin deficiency: lessons for the pulmonologist.

ERJ open research
2026

Severe Obesity and Alpha-1 Antitrypsin Deficiency-Associated COPD: A Dual Burden on Health and Quality of Life.

Chronic obstructive pulmonary diseases (Miami, Fla.)
2026

Robotic-assisted Left Pneumonectomy For Vanishing Lung Syndrome.

Journal of visualized experiments : JoVE
2026

Isolated GGT elevation in prolonged neonatal jaundice: detection of heterozygous alpha-1 antitrypsin deficiency.

BMJ case reports
2026

Functional and clinical significance of novel SERPINA1 variants on alpha-1 antitrypsin deficiency.

Respiratory research
2025

Neutrophil-derived extracellular vesicles in the plasma of alpha-1 antitrypsin deficient individuals reveal pro-inflammatory metabolic and transcriptomic signatures.

Extracellular vesicle
2025

Chronic Obstructive Pulmonary Disease in Never-Smokers-A Distinct Entity Within the COPD Spectrum.

Life (Basel, Switzerland)
2026

Advances in Precision Editing Therapies for Alpha-1 Antitrypsin Deficiency.

Human gene therapy
2026

Alpha-1 antitrypsin deficiency and cardiovascular disease: a review.

Respiratory research
2026

Alpha-1 antitrypsin deficiency in bronchiectasis: Evidence for an overlooked entity beyond COPD: A retrospective observational study.

Medicine
2026

The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD.

Alimentary pharmacology &amp; therapeutics
2026

Routine Blood Biomarkers in Patients With the PI*SZ Genotype of Alpha-1 Antitrypsin Deficiency: Data From the EARCO Registry.

Archivos de bronconeumologia
2026

Stretching the diagnosis: tracheobronchomegaly in alpha-1 antitrypsin deficiency or coexisting Mounier-Kuhn syndrome?

Thorax
2025

Early-onset bibasilar emphysema in a patient with PLCG2-related immune dysregulation.

Respiratory medicine case reports
2026

RNA editing for the treatment of alpha-1 antitrypsin deficiency.

Nucleic acids research
2026

COVID-19 outcomes in individuals with severe alpha-1 antitrypsin deficiency in Sweden.

Scientific reports
2026

Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA.

Therapeutic advances in respiratory disease
2025

Circulating C-terminal peptides and polymers of alpha-1 antitrypsin as putative markers of pediatric Pi*ZZ liver disease.

Frontiers in pediatrics
2025

Alvelestat for alpha-1 antitrypsin deficiency-associated emphysema: the hope for an oral treatment.

The European respiratory journal
2025

Co-occurrence of Alpha-1 Antitrypsin Deficiency (AATD) and Common Variable Immunodeficiency (CVID): A Case Report.

Cureus
2026

Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.

Gastroenterology
2026

Rapid design and production of Alpha-1 antitrypsin fusion proteins in a plant-based cell-free expression system.

Free radical biology &amp; medicine
2025

Prevalence of SERPINA1 mutations in a bronchiectasis cohort: implications of extended screening for alpha-1 antitrypsin deficiency.

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
2025

Inflammation-adjusted optimal serum cut-off alpha-1 antitrypsin values for detecting deficient patients: a cross-sectional analysis of the AVATAR cohort.

ERJ open research
2025

Quantitative CT of emphysema, wall thickness and mucus plugs in alpha-1-antitrypsin deficiency: relationship to clinical outcomes.

European radiology
2026

Protein Aggregates in Heterozygous Alpha-1 Antitrypsin Phenotype Is a Marker for Progressive Disease.

Gastro hep advances
2025

In Reference to Increased Risk of Cholesteatoma in Individuals With Alpha-1 Antitrypsin Deficiency: A Cohort Study.

The Laryngoscope
2025

In Response to Increased Risk of Cholesteatoma in Individuals With Alpha-1 Antitrypsin Deficiency: A Cohort Study.

The Laryngoscope
2025

Patient-reported outcome measures for use in patients with alpha-1-antitrypsin deficiency: results of a systematic selection process.

BMJ open respiratory research
2025

The phenotypic state of biallelic SERPINA1 Q0 variants in α1-antitrypsin deficiency.

ERJ open research
2025

Neonatal-Onset Transient Subcutaneous Nodules as an Atypical Initial Presentation of Alpha-1 Antitrypsin Deficiency.

Pediatric dermatology
2025

Characterization of a novel SERPINA1 variant carrying two missense mutations: molecular mechanisms and functional impact.

Orphanet journal of rare diseases
2025

Rare but relevant: Genetic liver disease in the general medical setting.

Clinical medicine (London, England)
2025

Lisdexamfetamine-Induced Angioedema and Leukocytoclastic Vasculitis: A Case Report.

The Australasian journal of dermatology
2025

Molecular insights on the mechanism of α1-antitrypsin condensate formation and maturation.

PLoS computational biology
2025

Matrix metalloproteinases and disease severity among PI*MZ and PI*ZZ individuals in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) cohort.

BMJ open respiratory research
2025

Quantitative analysis of chest computed tomography in alpha-1-antitrypsin deficiency.

Respiratory research
2025

The mechanism of pathogenic α1-antitrypsin aggregation in the human liver.

Proceedings of the National Academy of Sciences of the United States of America
2025

Case Report: α1-antitrypsin deficiency causing persistent pleural effusion and multilobar alveolar emphysema in a young dog.

Frontiers in veterinary science
2025

Rare liver diseases - Etiology, diagnosis and management: A review.

Biomolecules &amp; biomedicine
2025

Characterization of alpha-1 antitrypsin in a Pi∗ZZ patient with emphysema: a case report.

Respiratory medicine case reports
2025

The Epidemiology of Alpha-1 Antitrypsin Deficiency in Norway.

Clinical epidemiology
2025

Lung disease in never-smokers with severe α1-antitrypsin deficiency: the EARCO Registry.

ERJ open research
2025

A synergistic approach to curative liver therapy: multiplex CRISPR-Cas12a and repair drive for alpha-1 antitrypsin deficiency (AATD).

Annals of medicine and surgery (2012)
2025

Alpha-1 antitrypsin deficiency: genetics, clinical manifestations, AI prognostics, and advanced imaging in liver disease.

Annals of medicine and surgery (2012)
2026

Routine Blood Biomarkers and Lung Disease in Patients with Alpha-1 Antitrypsin Deficiency from the EARCO Registry.

Respiration; international review of thoracic diseases
2025

Is α1-antitrypsin deficiency a cardiovascular risk factor?

ERJ open research
2025

α1-Antitrypsin deficiency and increased risk of atrial fibrillation in two large population-based cohorts.

ERJ open research
2025

Applications of Artificial Intelligence in Alpha-1 Antitrypsin Deficiency: A Systematic Review from a Respiratory Medicine Perspective.

Medicina (Kaunas, Lithuania)
2025

Phenotypic Expression of Respiratory Diseases and Tailored Treatment in Patients with Intermediate Alpha-1 Antitrypsin Deficiency: Evidence from a Retrospective Analysis of a Selected Cohort of Patients.

Medicina (Kaunas, Lithuania)
2025

Prospective Multicenter Longitudinal Measurement of Liver Stiffness in School-Age Children With Cholestatic Liver Disease.

Gastro hep advances
2025

Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH.

Annals of hepatology
2025

Alpha-1 antitrypsin deficiency and granulomatosis with polyangiitis: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society
2025

Upadacitinib in a Refractory Case of Alpha-1 Antitrypsin Deficiency-Related Panniculitis.

Cureus
2025

Pediatric Liver Diseases: Next-Generation Therapies.

Clinics in liver disease
2025

PiComplutense (p.Pro393Thr): A novel SERPINA1 variant in Alpha-1 antitrypsin deficiency identified in two siblings.

Respiratory medicine case reports
2026

Lung transplantation for chronic obstructive pulmonary disease patients: an overview.

Current opinion in pulmonary medicine
2025

Strawberry Gingivitis as the Initial Manifestation of Granulomatosis with Polyangiitis in A Patient with Alpha-1 Antitrypsin Deficiency.

European journal of case reports in internal medicine
2025

Distribution of SERPINA1 gene mutations in patients with spontaneous pneumothorax: A cross-sectional study from a tertiary chest diseases clinic in Turkiye.

Medicine
2025

Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits.

Respiratory research
2025

Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice.

American journal of physiology. Gastrointestinal and liver physiology
2025

Plasma proteome correlations with liver stiffness in pediatric cholestasis implicate epithelial to mesenchymal transition.

Hepatology communications
2025

Pi*M Palermo Mutation in Bronchiectasis due to Alpha-1 Antitrypsin Deficiency: A Rare Genetic Cause.

Medeniyet medical journal
2025

Pulmonary rehabilitation and quality of life in alpha-1 antitrypsin deficiency: findings from a retrospective cohort study.

Thorax
2025

Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency.

The European respiratory journal
2025

Growth hormone resistance in children with chronic cholestatic liver disease and reduced skeletal muscle mass.

Journal of pediatric gastroenterology and nutrition
2025

Next-Generation Regenerative Therapies for Alpha-1 Antitrypsin Deficiency: Molecular Pathogenesis to Clinical Translation.

International journal of molecular sciences
2025

A new SERPINA1 null allele of the PI*S-plus type: PI*Q0Tegueste.

Gene
2026

Increased Risk of Cholesteatoma in Individuals With Alpha-1 Antitrypsin Deficiency: A Cohort Study.

The Laryngoscope
2025

A compact base editor rescues AATD-associated liver and lung disease in mouse models.

Molecular therapy : the journal of the American Society of Gene Therapy
2025

Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial.

Annals of medicine and surgery (2012)
2025

A cure for alpha-1? Novel therapeutics in alpha-1 antitrypsin deficiency.

The European respiratory journal
2025

Alpha-1 Antitrypsin Genotype Distribution in Patients with Emphysema.

International journal of chronic obstructive pulmonary disease
2025

Impact of Acute Kidney Injury on Mortality Outcomes in Patients Hospitalized for COPD Exacerbation: A National Inpatient Sample Analysis.

Journal of clinical medicine
2025

Administrative coding for alpha-1 antitrypsin deficiency including the pi*ZZ phenotype is accurate in Sweden.

Scandinavian journal of gastroenterology
2025

Prevalence of genetic mutations in Alpha-1 antitrypsin in patients with difficult-to-treat asthma in Colombia.

BMC pulmonary medicine
2025

Improving Screening for Alpha-1 Antitrypsin Deficiency in Adults with COPD.

Joint Commission journal on quality and patient safety
2025

Galectin-8 binding to alpha-1 antitrypsin is a physiological mechanism in healthy individuals but exacerbates the symptoms of alpha-1 antitrypsin deficiency.

Archives of biochemistry and biophysics
2026

Epidemiology of Alpha-1 Antitrypsin Deficiency in the Veterans Health Administration.

Annals of the American Thoracic Society
2025

Alpha-1 antitrypsin in COVID-19 patients: a dual-center screening study in Malaysia.

Annals of Saudi medicine
2025

Characterisation of patients with Alpha-1 antitrypsin deficiency using unsupervised machine learning tools.

Respiratory medicine
2025

A Mysterious Trigger for Serum Amyloid A (SAA)-Associated Amyloidosis: Insights From an Autopsy Study.

Cureus
2025

Performance of enhanced liver fibrosis test and indirect serum fibrosis markers for exclusion of advanced liver fibrosis in alpha-1 antitrypsin deficiency.

European journal of internal medicine
2025

Alpha-1 antitrypsin deficiency with the rare IZ phenotype presenting as cystic lung disease.

BMJ case reports
2025

Assessing inflammatory protein biomarkers in COPD subjects with and without alpha-1 antitrypsin deficiency.

Respiratory research
2025

Rethinking FIB-4: The hidden zonal bias in alpha-1 antitrypsin deficiency.

Hepatology communications
2025

Increased exacerbations and hospitalizations among PI*MZ compared to PI*MM individuals: an electronic health record analysis.

Respiratory research
2025

Alpha-1 Antitrypsin Deficiency: A Potential Cause of Poor Asthma Control.

The journal of allergy and clinical immunology. In practice
2025

Susceptibility of alpha-1 antitrypsin deficiency variants to polymer-blocking therapy.

JCI insight
2025

Physico-chemically different carbon nanomaterials may elicit similar inflammatory molecular pathways within the lungs of mice.

Toxicology research
2025

Clinical characteristics of AATD-related COPD patients vary with age at diagnosis: data from the EARCO international registry.

BMC pulmonary medicine
2025

Generation of an induced pluripotent stem cell line HHUUKDi013-A (ISRM-AATD-iPSC-3) from a pediatric patient of Alpha-I Antitrypsin Deficiency (AATD).

Stem cell research
2025

Alpha-1 antitrypsin modulates neutrophil phenotype and function: implications for inflammatory regulation.

Journal of leukocyte biology
2025

Alpha-1 Antitrypsin Deficiency-Associated panniculitis: A survey of lived experience.

PloS one
2025

Alpha-1 Antitrypsin Deficiency and Bronchial Asthma: Current Challenges.

Biomolecules
2025

Sleep apnea among individuals with Alpha-1 antitrypsin deficiency-associated lung disease.

Respiratory medicine
2025

Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosis.

JHEP reports : innovation in hepatology
2025

Molecular Advances in Cholestatic Liver Diseases.

Advances in anatomic pathology
2025

Can Proteomics Play a Significant Role in the Identification of Biomarkers for Alpha1-Antitrypsin Deficiency?

International journal of molecular sciences
2025

Effect of Alpha-1 Antitrypsin Deficiency on Zinc Homeostasis Gene Regulation and Interaction with Endoplasmic Reticulum Stress Response-Associated Genes.

Nutrients
2025

Delivering base editors to the liver and lungs in alpha-1 antitrypsin deficiency.

Nature biotechnology
2025

Clinical Utility of Non-Invasive Tests for Liver Fibrosis in People Living With Alpha-1 Antitrypsin Deficiency.

Liver international : official journal of the International Association for the Study of the Liver
2025

Quantification of serum elastase inhibitory activity in patients with pulmonary emphysema with and without alpha-1 antitrypsin deficiency.

PloS one
2025

Further Insights into Emphysema Progression and Lung Function Decline in MZ Alpha-1 Antitrypsin Deficiency.

Annals of the American Thoracic Society
2025

Underdiagnosis of Alpha-1 Antitrypsin Deficiency in Cirrhotic Liver Transplant Candidates: Findings From a Multicenter Retrospective Study.

Alimentary pharmacology &amp; therapeutics
2025

Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related Mortality.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025

Exome-based genotype-first reverse phenotyping using structured electronic health record data identifies novel SERPINA1 variants associated with liver markers and demonstrates a dominant effect for specific variants on liver phenotype.

Hepatology research : the official journal of the Japan Society of Hepatology
2025

Autophagy in cancer and protein conformational disorders.

FEBS letters
2025

Transamniotic Fetal Delivery of Human Alpha-1 Antitrypsin mRNA in a Healthy Rodent Model.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2025

Progression and Augmentation Therapy in PiSZ and PiZZ Alpha-1 Antitrypsin Deficiency: A Longitudinal Functional and Densitometric Study.

Biomolecules
2025

Neonatal Cholestasis: Exploring Genetic Causes and Clinical Outcomes.

Journal of paediatrics and child health
2025

Rationale and Design of the Alpha-1 Biomarkers Consortium Study.

Chronic obstructive pulmonary diseases (Miami, Fla.)
2025

Characterization of the Mmalton carrier's cohort within the EARCO (European Alpha- 1 Antitrypsin Research Collaboration) registry.

BMC pulmonary medicine
2025

Liver Disease and Prevalence of Liver Transplantation in Adults With ZZ Alpha-1 Antitrypsin Deficiency-A Meta-Analysis.

Liver international communications
2025

Deep Visual Proteomics maps proteotoxicity in a genetic liver disease.

Nature
2025

Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine.

Hepatology communications
2024

Pi∗S and Pi∗Z Alleles of SERPINA1 Gene Are Associated With Specific Variants of a BRD4-Independent Enhancer.

Human mutation
2026

Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates.

Nature biotechnology
2025

Trans-ancestry genome-wide association meta-analysis of gallstone disease.

medRxiv : the preprint server for health sciences
2025

Detection of nocturnal hypoxaemia leading to a diagnosis of COPD and PiMZ alpha-1 antitrypsin deficiency.

BMJ case reports
2024

Applied physiological principles in the management of a lung allograft to thoracic cavity size mismatch in severe emphysema.

JHLT open
2025

Lung transplant outcomes for recipients with alpha-1 antitrypsin deficiency, by use of alpha-1 antitrypsin augmentation therapy.

JHLT open
2025

The Role of Gene Therapy as an Emerging Treatment Strategy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease: A Systematic Review.

Cureus
2025

Refractory Hypokalemia of Pregnancy: A Rare Case of Non-Aldosterone Mediated Hypokalemia.

Cureus
2025

Chaperone-mediated autophagy degrades SERPINA1E342K/α1-antitrypsin Z variant and alleviates cell stress.

Autophagy
2025

Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy.

Journal of controlled release : official journal of the Controlled Release Society
2025

Densitometric and Functional Progression in Patients with Alpha-1 Antitrypsin Deficiency Genotype SZ.

Journal of clinical medicine
2025

Alpha-1 antitrypsin deficiency and risk of sleep apnea: a nationwide cohort study.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2025

Carrier Frequency of Autosomal Recessive Diseases in a Population Attending a Human Fertility Institute in Colombia.

JBRA assisted reproduction
2025

Patient experience of alpha-1 antitrypsin deficiency-associated liver disease: a qualitative study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
2025

Diagnosis and Monitoring Pathways Using Non-Invasive Tests in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease: Results From an Expert Delphi Panel.

United European gastroenterology journal
2025

Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin-Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort.

Annals of the American Thoracic Society
2025

Signs of Hyperinflation and Ventilation Heterogeneity in Individuals With Severe Alpha-1-Antitrypsin Deficiency at the Age of 42.

International journal of chronic obstructive pulmonary disease
2025

Selection for somatic escape variants in SERPINA1 in the liver of patients with alpha-1 antitrypsin deficiency.

Nature genetics
2025

Bacterial colonisation doubles the risk of exacerbation in alpha-1 antitrypsin deficiency.

Respiratory medicine
2025

Genetic Mutations and Post-Lung Transplant Complications: A Case of Hereditary Transthyretin Amyloidosis.

Transplantation proceedings
2025

Alpha-defensins increase NTHi binding but not engulfment by the macrophages enhancing airway inflammation in Alpha-1 antitrypsin deficiency.

Frontiers in immunology
2025

Pulmonary artery aneurysm as a rare manifestation of Alpha-1 antitrypsin deficiency.

Respiratory medicine case reports
2025

Alpha-1 antitrypsin deficiency and primary liver cancers.

Biochimica et biophysica acta. Reviews on cancer
2025

Clinical and Economic Outcomes in Patients With Alpha-1 Antitrypsin Deficiency in a US Medicare Advantage Population.

Journal of health economics and outcomes research
2025

Patient-centered assessment of treatment for alpha-1 antitrypsin deficiency: literature review to identify concepts and measures for people with alpha1-antitrypsin deficiency.

Orphanet journal of rare diseases
2024

Genetic characterization of a rare case of pheochromocytoma in a pulmonary transplant patient.

Frontiers in endocrinology
2025

Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency.

Therapeutic advances in respiratory disease
2025

Alpha-1 Antitrypsin Deficiency Screening Using Serum Protein Electrophoresis.

Respiratory care
2025

An Electronic Health Record-Based Strategy to Enhance Detection of Alpha-1 Antitrypsin Deficiency.

Respiratory care
2025

More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency.

Hepatology (Baltimore, Md.)
2025

α1-Antitrypsin Gene Variation Associates With Asthma Exacerbations and Related Health Care Utilization.

The journal of allergy and clinical immunology. In practice
2025

Proposal and Validation of the Minimum Clinically Important Difference in Emphysema Progression.

Chronic obstructive pulmonary diseases (Miami, Fla.)
2025

Panniculitis: a narrative review.

Archives of dermatological research
2025

Plasma Extracellular Vesicle-derived MicroRNA Associated with Human Alpha-1 Antitrypsin Deficiency-mediated Liver Disease.

Journal of clinical and translational hepatology
2025

Vascular Pathology in Alpha 1 Antitrypsin Deficient Chronic Obstructive Pulmonary Disease and Emphysema Patients: Case Reports.

The application of clinical genetics
2025

Generation of a human induced pluripotent stem cell (iPSC) line ERPLi004-A from an Alpha-1 antitrypsin deficiency (AATD) patient with SERPINA1 mutation.

Stem cell research
2025

Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline.

Chest
2025

Risk of lung disease with the Pi*SS genotype of alpha-1 antitrypsin: the evidence in context.

Respiratory research
2025

Making Proteins with Electricity.

Reviews of physiology, biochemistry and pharmacology
2025

Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review.

Patient related outcome measures
2025

Spatial covariance reveals isothiocyanate natural products adjust redox stress to restore function in alpha-1-antitrypsin deficiency.

Cell reports. Medicine
2025

Self-administration of augmentation therapy for alpha 1-antitrypsin deficiency.

IJTLD open
2025

Identification of an exosite at the neutrophil elastase/alpha-1-antitrypsin interface.

The FEBS journal
2025

Epidemiology and outcomes of alpha-1 antitrypsin deficiency in Sweden 2002-2020: A population-based cohort study of 2286 individuals.

Journal of internal medicine
2024

Can Quality of Life Tests Be Useful in Patients Affected by Alpha-1 Antitrypsin Deficiency?

Journal of clinical medicine
2025

Regarding: Alpha-1 antitrypsin deficiency associated with increased risks of skin cancer, leukemia, and hepatic cancer: A nationwide cohort study.

Journal of internal medicine
2024

Alpha-1 antitripsyn deficiency and augmentation therapy in pregnancy: two case reports.

Frontiers in medicine
2024

Clinical implications of the SERPINA1 variant, MPalermo, and alpha-1 antitrypsin deficiency in Türkiye.

BMC pulmonary medicine
2024

COVID-19 in Individuals with Severe Alpha 1-Antitrypsin Deficiency.

International journal of chronic obstructive pulmonary disease
2025

Alpha-1 Antitrypsin Inclusions Sequester GRP78 in a Bile Acid-Inducible Manner.

Liver international : official journal of the International Association for the Study of the Liver
2024

Alpha-1 Antitrypsin Deficiency: Navigating Challenges Through Collaborative Innovation.

Chest
2024

Recommendations for the diagnosis and treatment of alpha-1 antitrypsin deficiency.

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
2025

Thresholds for conjugated hyperbilirubinaemia and hepatobiliary scintigraphy in biliary atresia: A 12-year national follow-up.

Acta paediatrica (Oslo, Norway : 1992)
2025

Fazirsiran Unveiled: Methodological Considerations for Optimizing Treatment in Alpha-1 Antitrypsin Deficiency.

Gastroenterology
2025

Novel Lobe-based Transformer model (LobTe) to predict emphysema progression in Alpha-1 Antitrypsin Deficiency.

Computers in biology and medicine
2025

KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency.

Chronic obstructive pulmonary diseases (Miami, Fla.)
2025

Improving the Likelihood of Identifying Alpha-1 Antitrypsin Deficiency Among Patients With COPD: A Novel Predictive Model Using Real-World Data.

Chronic obstructive pulmonary diseases (Miami, Fla.)
2025

Clinical features in patients with severe Alpha-1 antitrypsin deficiency due to rare genotypes.

Pulmonology
2024

European Alpha-1 Research Collaboration (EARCO) in Portugal: The Future Is Happening.

Acta medica portuguesa
2025

Goals of chronic obstructive pulmonary disease management: a focused review for clinicians.

Current opinion in pulmonary medicine
2024

Quantitative BAL: a suitable method for the assessment of epithelial lining fluid in alpha-1 antitrypsin deficiency?

Thorax
2024

Optimising bronchoalveolar lavage: lessons from alpha-1 antitrypsin deficiency.

Thorax
2025

A unique case of steroid-resistant, giant cellulitis-like Sweet syndrome mimicking alpha-1-antitrypsin deficiency-associated panniculitis: successful treatment with dapsone.

Clinical and experimental dermatology
Ver todos os 2.054 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Associação brasileira dedicada a Deficiência de alfa-1 antitripsina.

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Deficiência de alfa-1 antitripsina

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Original research: Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency.
    Hepatology (Baltimore, Md.)· 2026· PMID 41812027mais citado
  2. Prevalence of liver disease and liver transplantation in pediatric ZZ alpha-1 antitrypsin deficiency: A systematic review and meta-analysis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver· 2026· PMID 41791905mais citado
  3. Alpha-1 Antitrypsin Deficiency in Patients With Cirrhosis in a US National Cohort.
    Clinical and translational gastroenterology· 2026· PMID 41696918mais citado
  4. Isolated GGT elevation in prolonged neonatal jaundice: detection of heterozygous alpha-1 antitrypsin deficiency.
    BMJ case reports· 2026· PMID 41629111mais citado
  5. Advances in Precision Editing Therapies for Alpha-1 Antitrypsin Deficiency.
    Human gene therapy· 2026· PMID 41588875mais citado
  6. AT2-intrinsic Z-AAT expression drives conserved inflammatory and proteotoxic stress responses and predisposes to emphysema.
    bioRxiv· 2026· PMID 41993529recente
  7. Affinity Proteomics-Based Non-Invasive Detection of Clinically Significant Liver Disease.
    Aliment Pharmacol Ther· 2026· PMID 41992602recente
  8. Alpha-1 Antitrypsin Replacement Improves Walking Capacity in Subjects With Severe Deficiency.
    Respir Care· 2026· PMID 41979019recente
  9. From Birth to Midlife-Liver Function, Fibrosis and Mortality in Individuals with Severe Alpha-1-Antitrypsin Deficiency Identified by Neonatal Screening.
    J Clin Med· 2026· PMID 41976854recente
  10. Z variant heterozygosity in alpha-1 antitrypsin deficiency: disease risk and treatment implications.
    Orphanet J Rare Dis· 2026· PMID 41952152recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:60(Orphanet)
  2. OMIM OMIM:613490(OMIM)
  3. MONDO:0013282(MONDO)
  4. GARD:5784(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q622437(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Deficiência de alfa-1 antitripsina
Compêndio · Raras BR

Deficiência de alfa-1 antitripsina

ORPHA:60 · MONDO:0013282
Prevalência
1-5 / 10 000
Herança
Autosomal recessive
CID-10
E88.0 · Distúrbios do metabolismo das proteínas plasmáticas não classificados em outra parte
CID-11
Ensaios
26 ativos
Medicamentos
1 registrados
Início
All ages
Prevalência
47.5 (Ireland)
MedGen
UMLS
C0221757
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades